Design of selective peptidomimetic agonists for the human orphan receptor BRS-3

Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2003, Pages 1918-1930

  Weber, Dirk ^a   Berger, Claudia ^b   Eickelmann, Peter ^b,c   Antel, Jochen ^b   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE DERIVATIVE; AZAGLYCINE; BOMBESIN RECEPTOR; DEXTRO PHENYLALANYLGLUTAMINE DEXTRO TRYPTOPHAN 1 (2 PHENYLETHYL)AMIDE; G PROTEIN COUPLED RECEPTOR; GLYCINE DERIVATIVE; ORPHAN RECEPTOR; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; RECEPTOR SUBTYPE; SEMICARBAZIDE DERIVATIVE; SEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CANCER; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CHO CELL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; FLUOROMETRY; HUMAN; MOLECULAR STABILITY; MOLECULAR WEIGHT; NONHUMAN; OBESITY; RECEPTOR AFFINITY; SOLID; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TECHNIQUE;

ANIMALS; AZA COMPOUNDS; CALCIUM; CHO CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; HUMANS; MOLECULAR MIMICRY; OLIGOPEPTIDES; PEPTIDES; RECEPTORS, BOMBESIN; SEMICARBAZIDES; SEMICARBAZONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038754759     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0210921     Document Type: Article

References (106)

1. Drews, J. Drug Discovery: A Historical Perspective. Science 2000, 287 (5460), 1960-1963.
2. Source: IMS Health, Fairfield, CT (2001).
3. (a) Stadel, J. M.; Wilson, S.; Bergsma, D. J. Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. Trends Pharmacol. Sci. 1997, 18, 430-437.
4. (b) Wilson, S.; Bergsma, D. J.; Chambers, J. K.; Muir, A. I.; Fantom, K. G. M.; Ellis, C.; Murdock, P. R.; Herrity, N. C.; Stadel, J. M. Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol. 1998, 125 (7), 1387-1392.
5. Dowell, S. J. Understanding GPCRs-from orphan receptors to novel drugs. Drug Discovery Today 2001, 6 (17), 884-886.
6. (a) International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
7. (b) Venter, J. C.; et al. The sequence of the human genome. Science 2001, 291, 1304-1351.
8. (a) Libert, F.; Vassart, G.; Parmentier, M. Current developments in G-protein coupled receptors. Curr. Opin. Cell Biol. 1991, 8, 218-223.
9. (b) Civelli, O. Functional genomics: the search for novel neurotransmitters and neuropeptides. FEBS Lett. 1998, 430, 55-58.
10. (c) Civelli, O.; Reinscheid, R.; Nothacker, H.-P. Orphan receptors, novel neuropeptides and reverse pharmaceutical research. Brain Res. 1999, 848, 63-65.
11. (d) Civelli, O.; Saito, Y.; Lin, S.; Nothacker, H.-P.; Renscheid, R.; Wang, Z. The orphan receptor strategy and the discovery of novel neuropeptides. Trends Neurosci. 2001, 24, 230-237.
12. For a review, see the following. Chalmers, D. T.; Behan, D. P. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Discovery 2002, 1, 103-110.
13. Gether, U.; Kobilka, B. K. G-protein coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 1998, 273, 17979-17982.
14. Schwartz, T. W.; Rosenkilde, M. M. Is there a "lock" for all agonist "keys" in 7TM receptors? Trends Pharmacol. Sci. 1996, 17, 213-216.
15. Wess, G.; Urmann, M.; Sickenberger, B. Medicinal Chemistry: Challenges and Opportunities. Angew. Chem., Int. Ed. 2001, 40, 3341-3350.
16. Fathi, Z.; Corjay, M. H.; Shapira, H.; Wada, E.; Benya, R.; Jensen, R.; Viallet, J.; Sausville, E. A.; Battey, J. F. BRS-3: A Novel Bombesin Receptor Subtype Selectively Expressed in Testis and Lung Carcinoma Cells. J. Biol. Chem. 1993, 268, 5979-5984.
17. Gorbulev, V.; Akhundova, A.; Büchner, H.; Fahrenholz, F. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy. Eur. J. Biochem. 1992, 208, 405-410.
18. (a) Okhi-Hamazaki, H.; Watase, K.; Yamamoto, K.; Ogura, H.; Yamano, M.; Yamada, K.; Maeno, H.; Imaki, J.; Kikuyama, S.; Wada, E.; Wada, K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 1997, 390, 165-169.
19. (b) Yamada, K.; Wada, E.; Imaki, J.; Ohki-Hamazaki, H.; Wada, K. Hyperresponsiveness to Palatable and Aversive Taste Stimuli in Genetically Obese (Bombesin Receptor Subtype-3-Deficient) Mice. Physiol. Behav. 1999, 66, 863-867.
20. (a) DeMichele, M. A.; Davis, A. L.; Hunt, J. D.; Landreneau, R. J.; Siegfried, J. M. Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 1994, 11, 66-74.
21. (b) Toi-Scott, M.; Jones, C. L.; Kane, M. A. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells. Lung Cancer 1996, 15, 341-354.
22. (c) Kiaris, H.; Schally, A. V.; Nagy, A.; Sun, B.; Armatis, P.; Szepeshazi, K. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. Br. J. Cancer 1999, 81, 966-971.
23. (d) Sun, B.; Schally, A. V.; Halmos, G. The presence of receptors for bombesin/GRP and mRNA for the three receptor subtypes in human ovarian epithelial cancers. Regul. Pept. 2000, 90, 77-84.
24. (a) Cuttitta, F.; Carney, N.; Mulshine, J.; Moody, T. W.; Fedorko, J.; Fischler, A.; Minna, J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985, 316, 823-826.
25. (b) Carney, D. N.; Cuttitta, F.; Moody, T. W.; Minna, J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987, 47, 821-825.
26. (a) Gorbulev, V.; Akhundova, A.; Grzeschick, K. H.; Fahrenholz, F. Organization and chromosomal localization of the gene for the human bombesin receptor subtype expressed in pregnant uterus. FEBS Lett. 1994, 340, 260-264.
27. (b) Okhi-Hamazaki, H.; Wada, E.; Matsui, K.; Wada, K. Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse. Brain Res. 1997, 762, 165-172.
28. (c) Whitley, J. C.; Moore, C.; Giraud, A. S.; Shulkes, A. Molecular cloning, genomic organization and selective expression of bombesin receptor subtype 3 in the sheep hypothalamus and pituitary. J. Mol. Endocrinol. 1999, 23, 107-116.
29. Liu, J.; Lao, Z. J.; Zhang, J.; Schaeffer, M. T.; Jiang, M. M.; Guan, X.-M.; Van der Ploeg, L. H. T.; Fong, T. M. Molecular Basis of the Pharmacological Difference between Rat and Human Bombesin Receptor Subtype-3 (BRS-3). Biochemistry 2002, 41, 8954-8960.
30. (a) Vigna, S. R.; Giraud, A. S.; Soll, A. H.; Walsh, J. H.; Mantyn, P. W. Bombesin Receptors on Gastrin Cells. Ann. N. Y. Acad. Sci. 1988, 547, 131-137.
31. (b) Battey, J.; Wada, E. Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci. 1991, 14, 524-528.
32. (c) Battey, J. F.; Way, J. M.; Corjay, M. H.; Shapira, H.; Kusano, K.; Harkins, R.; Wu, J.; Slattery, T.; Mann, E.; Feldman, R. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 395-399.
33. (d) Wada, E.; Way, J.; Shapira, H.; Kusano, K.; Lebacq-Verheyden, A.; Coy, D. H.; Jensen, R. T.; Battey, J. F. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron 1991, 6, 421-430.
34. (e) Vigne, P.; Feolde, E.; Van Renterghem, C.; Breittmayer, J. P.; Frelin, C. Properties and functions of a neuromedin-B-preferring bombesin receptor in brain microvascular endothelial cells. Eur. J. Biochem. 1995, 233, 414-418.
35. Smart, D.; Strijbos, P. Bombesin receptor subtype 3 polynucleotides, polypeptides and ligands for use in treating neurological disorders. PTC Int. Appl. WO 0168120, 2001; 31 pp.
36. (a) Mantey, S. A.; Weber, H. C.; Sainz, E.; Akeson, M.; Ryan, R. R.; Pradhan, T. K.; Searles, R. P.; Spindel, E. R.; Battey, J. F.; Coy, D. H.; Jensen, R. T. Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors. J. Biol. Chem. 1997, 272, 26062-26071.
37. (b) Pradhan, T. K.; Katsuno, T.; Taylor, J. E.; Kim, S. H.; Ryan, R. R.; Mantey, S. A.; Donohue, P. J.; Weber, H. C.; Sainz, E.; Battey, J. F.; Coy, D. H.; Jensen, R. T. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur. J. Pharmacol. 1998, 343, 275-287.
38. (c) Mantey, S. A.; Coy, D. H.; Pradhan, T. K.; Igarashi, H.; Rizo, I. M.; Shen, L.; Hou, W.; Hocart, S.; Jensen, R. T. Rational Design of a Peptide Agonist That Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtype 3. J. Biol. Chem. 2001, 276, 9219-9229.
39. Ryan, R. R.; Weber, H. C.; Hou, W.; Sainz, E.; Mantey, S. A.; Battey, J. F.; Coy, D. H.; Jensen, R. T. Ability of Various Bombesin Receptor Agonists and Antagonists To Alter Intracellular Signaling of the Human Orphan Receptor BRS-3. J. Biol. Chem. 1998, 273, 13613-13624.
40. Weber, D.; Berger, C.; Heinrich, T.; Eickelmann, P.; Antel, J.; Kessler, H. Systematic Optimization of a Lead-Structure Identities for a Selective Short Peptide Agonist for the Human Orphan Receptor BRS-3. J. Pept. Sci. 2002, 8, 461-475.
41. 2). J. Pept. Sci. 2001, 7, 598-605.
42. (a) Horwell, D. C.; Howson, W.; Rees, D. C. "Peptoid" Design. Drug Des. Discovery 1994, 12, 63-75.
43. (b) Horwell, D. C. The "peptoid" approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. Trends Biotechnol. 1995, 13, 132-134.
44. (c) Horwell, D. C. Design of non-peptide agonists and antagonists at neuropeptide receptors starting from the chemical structure of neuropeptides. Lett. Pept. Sci. 1998, 5, 115-116.
45. (a) Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R. S.; Roberts, E.; Woodruff, G. N. Rationally Designed "Dipeptoid" Analogues of CCK. α-Methyltryptophan Derivatives as Highly Selective and Highly Active Gastrin and CCK-B Antagonists with Potent Anxiolytic Properties. J. Med. Chem. 1991, 34, 404-414.
46. (b) Boden, P. R.; Higginbottom, M.; Hill, D. R.; Horwell, D. C.; Hughes, J.; Rees, D. C.; Roberts, E.; Singh, L.; Suman-Chauhan, N.; Woodruff, G. N. Cholecystokinin Dipeptoid Antagonists: Design, Synthesis and Anxiolytic Profile of Some Novel CCK-A and CCK-B Selective and "Mixed" CCK-A/CCK-B Antagonists. J. Med. Chem. 1993, 36, 552-565.
47. (c) Singh, L.; Field, M. J.; Hill, D. R.; Horwell, D. C.; McKnight, A. T.; Roberts, E.; Tang, K. W.; Woodruff, G. N. Peptoid CCK Receptor Antagonists: Pharmacological Evaluation of CCKA, CCKB and Mixed CCKA/B Receptor Antagonists. Eur. J. Pharmacol. 1995, 286, 185-191.
48. (d) Trivedi, B. K.; Padia, J. K.; Holmes, A.; Rose, S.; Wright, D. S.; Hinton, J. P.; Pritchard, M. C.; Eden, J. M.; Kneen, C.; Webdale, L.; Suman-Chauhan, N.; Boden, P.; Singh, L.; Field, M. J.; Hill, D. Second Generation "Peptoid" CCK-B Receptor Antagonists: Identification and Development of N-(Adamantyloxycarbonyl)-α-methyl-(R)-tryptophan Derivative (CI-1015) with an Improved Pharmacokinetic Profile. J. Med. Chem. 1998, 41, 38-45.
49. 2 Receptor Antagonists. Bioorg. Med. Chem. 1994, 2, 101-113.
50. 3 Receptor Selective Antagonists. J. Med. Chem. 1996, 39, 1664-1675.
51. 2 Receptor Antagonist. Eur. J. Pharmacol. 1993, 234, 83-90.
52. 3 Receptor Selective Antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 1773-1778.
53. (a) Eden, J. M.; Hall, M. D.; Higginbottom, M.; Horwell, D. C.; Howson, W.; Hughes, J.; Jordan, R. E.; Lewthwaite, R. A.; Martin, K.; McKnight, A. T.; O'Toole, J. C.; Pinnock, R. D.; Pritchard, M. C.; Suman-Chauhan, N.; Williams, S. C. PD 165929 - The First High Affinity Non-Peptide Neuromedin-B (NMB) Receptor Selective Antagonist. Bioorg. Med. Chem. Lett. 1996, 6, 2617-2622.
54. 2) Receptor Antagonist. Bioorg. Med. Chem. Lett. 1998, 8, 2589-2594.
55. Simon, R. J.; Kania, R. S.; Zuckermann, R. N.; Huebner, V. D.; Jewell, D. A.; Banville, S.; Ng, S.; Wang, L.; Rosenberg, S.; Marlowe, C. K.; Spellmeyer, D. C.; Tan, R.; Frankel, A. D.; Santi, D. V.; Bartlett, P. A. Peptoids: A modular approach to drug discovery. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 9367-9371.
56. Zuckermann, R. N.; Kerr, J. M.; Kent, S. B. H.; Moos, W. H. Efficient Method for the Preparation of Peptoids [Oligo(N-substituted glycines)] by Submonomer Solid-Phase Synthesis. J. Am. Chem. Soc. 1992, 114, 10646-10647.
57. Kessler, H. Peptoids: key compounds in a new path to pharmaceutically active substances. Angew. Chem., Int. Ed. Engl. 1993, 32, 543-544.
58. Miller, S. M.; Simon, R. J.; Ng, S.; Zuckermann, R. N.; Kerr, J. M.; Moos, W. H. Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorg. Med. Chem. Lett. 1994, 4, 2657-2662.
59. (a) Zuckermann, R. N.; Martin, E. J.; Spellmeyer, D. C.; Stauber, G. B.; Shoemaker, K. R.; Kerr, J. M.; Figliozzi, G. M.; Goff, D. A.; Siani, M. A.; Simon, R. J.; Banville, S. C.; Brown, E. G.; Wang, L.; Richter, L. S.; Moos, W. H. Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library. J. Med. Chem. 1994, 37, 2678-2685.
60. Hamy, F.; Felder, E. R.; Heizmann, G.; Lazdins, J.; Aboul-ela, F.; Varani, G.; Karns, J.; Klimkait, T. An inhibitor of the TAT/TAR RNA interaction that effectively suppresses HIV-1-replication. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3548-3553.
61. For a review, see the following. Gante, J. Azapeptides. Synthesis 1989, 6, 405-413.
62. Gante, J. Peptidomimetics-tailored enzyme inhibitors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699-1720.
63. (a) Bold, G.; Fässler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hürlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development. J. Med. Chem. 1998, 41, 3387-3401.
64. (b) Witherell, G. Novartis/Bristol-Myers Squibb. Curr. Opin. Invest. Drugs 2001, 2, 340-347.
65. Floersheimer, A.; Riniker, B. Solid-phase synthesis of peptides with the highly acid-sensitive HMPB linker. Proc. Eur. Pept. Symp., 21th, 1990 1991, 131.
66. Dörner, B.; White, P. Preparation of carboxy-modified peptide fragments using alkoxybenzaldehyde resins. Proc. Eur. Pept. Symp., 25th, 1998, 1999, 90.
67. 41 Hydrolysis of the ester with aqueous NaOH yielded 7g.
68. (a) Gretler, R.; Askitoglu, E.; Kühne, H.; Hesse, M. Die massenspektrometrische retro-Diels - Alder-Reaktion: 1,2,3,4-Tetrahydroisochinolin und 1,2,3,4-Tetrahydronaphthalin (Tetralin) (The mass spectrometry of retro-Diels - Alder reaction: 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydronaphthalene (Tetralin). Helv. Chim. Acta 1978, 61 (5), 1730-1755.
69. (b) Pelletier, J. C.; Cava, M. P. The Reaction of 3,4-Dihydroisoquinolines with Malonic Acid and Its Derivatives. Synthesis 1987, 5, 474-477.
70. Carpino, L. A.; Han, G. Y. The 9-Fluorenylmethoxycarbonyl Amino-Protecting Group. J. Org. Chem. 1972, 37, 3404-3409.
71. (a) Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco, G.; Loi, A. G.; Tramontano, E.; Marongiu, M. E.; La Colla, P. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4- dihydropyrimidin-4(3H)-ones: Novel Potent and Selective Dihydroalkoxy-benzyl-oxopyrimidine Derivatives. J. Med. Chem. 1999, 42, 619-627.
72. (b) Moody, C. J.; Rahimtoola, F. Diels - Alder Reactivity of Pyrano[4,3-b]indol-3-ones, Indole 2,3-Quinodimethane Analogues. J. Chem. Soc., Perkin Trans. 1 1990, 673-679.
73. (a) Fields, G. B.; Noble, R. L. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.
74. (b) Chan, C.; White, D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach; Oxford University Press: Oxford, 2000.
75. (a) König, W.; Geiger, R. Chem. Ber. 1970, 103, 788-798.
76. (b) König, W.; Geiger, R. Chem. Ber. 1970, 103, 2024-2033.
77. (a) Speziale, A. J.; Jaworski, E. G. N-Substituted Glycinate and Alaninate Esters. J. Org. Chem. 1960, 25, 728-732.
78. (b) Stewart, H. C. A Surface Active Sydnone. Austr. J. Chem. 1961, 14, 654-656.
79. Dechantsreiter, M. Doctoral Thesis, Technical University of Munich, Germany, 1998.
80. (a) Dourtoglou, V.; Gross, B.; Lambropoulou, V.; Zioudrou, C. O-Benzotriazolyl-N,N,N′,N′-tetramethyluronium hexafluorophosphate as coupling reagent for the synthesis of peptides of biological interest. Synthesis 1984, 7, 572-574.
81. (b) Carpino, L. A.; 1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
82. White, P. Fmoc-Trp(Boc)-OH: A new derivative for the synthesis of peptides containing tryptophan. Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 12th 1992, 537-538.
83. Han, H.; Janda, K. D. Azatides: Solution and Liquid Phase Synthesis of a New Peptidomimetic. J. Am. Chem. Soc. 1996, 118 (11), 2539-2544.
84. (a) Wermuth, J. Doctoral Thesis, Technical University of Munich, Germany, 1996.
85. (b) Schmitt, J. S. Doctoral Thesis, Technical University of Munich, Germany, 1998.
86. (a) Quibell, M.; Turnell, W. G.; Johnson, T. Synthesis of Azapeptides by the Fmoc/tert-Butyl/Polyamide Technique. J. Chem. Soc., Perkin Trans. 1 1993, 2843-2849.
87. (b) Liley, M.; Johnson, T. Solid phase synthesis of azapeptides utilizing reversible amide bond protection to prevent hydantoin formation. Tetrahedron Lett. 2000, 41, 3983-3985.
88. (a) André, F.; Marraud, M.; Tsouloufis, T.; Tzartos, S. J.; Boussard, G. Triphosgene: an efficient carbonylating agent for liquid and solid-phase aza-peptide synthesis. Application to the synthesis of two aza-analogues of the AchR MIR decapeptide. J. Pept. Sci. 1997, 3, 429-441.
89. (b) Frochot, C.; Vanderesse, R.; Driou, A.; Linden, G.; Marraud, M.; Cung, M. T. A solid-phase synthesis of three aza-, iminoaza- and reduced aza-peptides from the same precursor. Lett. Pept. Sci. 1997, 4, 219-225.
90. (a) Gibson, C.; Goodman, S. L.; Hahn, D.; Hölzemann, G.; Kessler, H. Novel Solid-Phase Synthesis of Azapeptides and Azapeptoides via Fmoc-Strategy and Its Application in the Synthesis of RGD-Mimetics. J. Org. Chem. 1999, 64, 7388-7394.
91. (b) Gibson, C.; Sulyok, G. A. G.; Hahn, D.; Goodman, S. L.; Hölzemann, G.; Kessler, H. Nonpeptidic αvβ3 Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Angew. Chem., Int. Ed. 2001, 40, 165-169.
92. (c) Sulyok, G. A. G.; Gibson, C.; Goodman, S. L.; Hölzemann, G.; Wiesner, M.; Kessler, H. Solid-Phase Synthesis of a Nonpeptide RGD Mimic Library: New Selective αvβ3 Integrin Antagonists. J. Med. Chem. 2001, 44, 1938-1950.
93. Wright, S. W.; Hageman, D. L.; McClure, L. D. Fluoride-Mediated Boronic Acid Coupling Reactions. J. Org. Chem. 1994, 59, 6095-6097.
94. Dutta, A. S.; Morley, J. S. Polypeptides. Part XIII. Preparation of α-Aza-amino-acid (Carbazic Acid) Derivatives and Intermediates for the Preparation of α-Aza-peptides. J. Chem. Soc., Perkin Trans. 1 1975, 17, 1712-1720.
95. Calabretta, R.; Giordano, C.; Gallina, C.; Morea, V.; Consalvi, V.; Scandurra, R. Peptidyl and azapeptidyl methylketones as substrate analog inhibitors of papain and cathepsin B. Eur. J. Med. Chem. 1995, 30 (12), 931-941.
96. Hansen, T. K. Synthesis of azapeptides from hindered amines leading to novel growth hormone secretagogues. Tetrahedron Lett. 1999, 40 (51), 9119-9120.
97. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
98. (a) Reynolds, C. H.; Hormann, R. E. Theoretical study of the structure and rotational flexibility of diacylhydrazines: Implications for the structure of nonsteroidal ecdysone agonists and azapeptides. J. Am. Chem. Soc. 1996,118, 9395-9401.
99. (b) André, F.; Boussard, G.; Bayeul, D.; Didierjean, C.; Aubry, A.; Marraud, M. Aza-peptides. II. X-Ray structures of aza-alanine and aza-asparagine containing peptides. J. Pept. Res. 1997, 49, 556-562.
100. (c) André, F.; Vicherat, A.; Boussard, G.; Aubry, A.; Marraud, M. Aza-peptides. III. Experimental structural analysis of aza-alanine and aza-asparagine-containing peptides. J. Pept. Res. 1997, 50, 372-381.
101. (d) Lee, H.-J.; Anh, I.-A.; Ro, S.; Choi, K.-H.; Choi, Y.-S.; Lee, K.-B. Role of azaamino acid residue in β-turn formation and stability in designed peptide. J. Pept. Res. 2000, 56, 35-46.
102. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem., Int. Ed. 1997, 3, 11374-11389.
103. 12]bombesin analogs: a new class of bombesin receptor antagonists. Am. J. Physiol. 1987, 252, G439-G442.
104. Thomas, F.; Arvelo, F.; Antoine, E.; Jacrot, M.; Poupon, M. F. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression. Cancer Res. 1992, 52, 4872-4877.
105. th 1990, 65-67.
106. 50 ± SEM. Values exceeding 10 nM have been approximated to the full number, values exceeding 100 nM to the full 10, and values larger than 1000 nM to the full 100.